Loading
TNG456 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for non-small-cell lung cancer and glioma & glioblastoma, aimed at PRMT5 (MTAP-deleted cancers).
TNG456 is a small-molecule drug developed by Tango Therapeutics. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and glioma & glioblastoma. The largest, NCT06810544, plans to enrol 191 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma. Connects to PRMT5 (MTAP-deleted cancers).
1.TNG456 slips into a pocket on PRMT5 (MTAP-deleted cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TNG456" OR ABSTRACT:"TNG456") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNG456, not a curated reading list.
Shares Tango Therapeutics, PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares Tango Therapeutics and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares Tango Therapeutics and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.